OptimizeRx Launches New Brand Suitability Technology, Enabling Dynamic Direct-to-Consumer Marketing for Healthcare Target Groups Page 1

WALTHAM, Ma., Sept. 9, 2024 (GLOBE NEWSWIRE) — OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions that help life sciences companies reach and engage healthcare professionals (HCPs) and prospective patients, today announced the company’s leading AI-driven consumer healthcare marketing technology, Micro-Neighborhood Targeting (MNT), offered on the Company’s Dynamic Audience Activation Platform (DAAP), which now further unifies patient and provider reach through the integration of brand fit signals into consumer marketing. This enhancement to DAAP enables pharmaceutical brands to deliver synchronized, AI-driven Direct-to-Consumer (DTC) and HCP campaigns, with the mission of improving the dialogue between patients and physicians throughout the treatment journey.

Innovative Life Sciences Marketing Using AI to Predict Care Windows

DAAP predicts potential fit for life science brands within the U.S. population and uses that prediction to precisely time point-of-care messages to treating HCPs during that time. Dynamic precision targeting has demonstrated significantly higher script lift than traditional forms of targeting and is now being applied to refresh MNT consumer audiences as the AI ​​learns the patterns that predict brand fit.

By pairing these AI-predicted brand fit signals with MNT, the company can help life science brands identify the most impactful moments to engage consumers in healthcare. By leveraging real-world data (RWD) through advanced machine learning models, DAAP deploys personalized, highly relevant brand communications from its own point-of-care network and digital media channels to advanced TV, programmatic display, video, social media and streaming radio.

“OptimizeRx solves the longstanding problem of siloed and disconnected marketing efforts. With DAAP, we can simultaneously deliver a variety of media with AI-driven predictive targeting to brand-appropriate patients and their treating healthcare providers,” said Steve Silvestro, the company’s president. “We deliver greater value to our customers by leveraging our technology and life sciences expertise to deliver solutions with measurable commercial impact. More than 300 leading pharmaceutical brands trust us because we achieve superior audience quality that is privacy-safe, delivers data-rich insights faster than traditional methods, and is generally more cost-effective for marketing. Our customers are asking for greater alignment between their physician and patient audiences because they know they will achieve better outcomes, and we help them achieve that.”